CD274 and small cell lung carcinoma: In extensive-stage small cell lung cancer (ES-SCLC), the addition of anti-PD-L1 in two recent randomised trials; CASPIAN [40–42] And Impower 133 has shown survival benefits over chemotherapy alone, albeit modest [36–38].